Clinical Trial

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Study acronym: Norseman
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-22; most recent amendment 2024-01-10.
Status change: Not Yet Recruiting → Recruiting 2023-06-21
Trial Details
NCT Number NCT05740722
Lead Sponsor Haukeland University Hospital
Conditions Multiple Sclerosis, Progressive Multiple Sclerosis
Enrollment 300 participants
Start Date 2023-05-03
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-01-11